Chronic kidney disease undergoing hemodialysis Chronic renal failure
Conditions
Interventions
To assess the adsorption properties of PMMA and PS membrane used for chronic kidney disease patients undergoing hemodialysis treatment.
Renal dialysis
PMMA, adsorption, hemodialysis
Sponsors
Yamamoto Suguru
Narita Ichiei
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet the all inclusion criteria as bellow, 1. Patients who can obtain written informed consent to participate in this study based on their free will. 2. Patients whose age is between 20 and 100 years old. 3. Patients undergoing hemodialysis treatment 4. Patients whose vascular access can keep blood flow more than 200 mL/minute 5. Patients who use hemodialyzer sized 1.5-2.5 m2 6. Patients with blood hemoglobin > 10 g/dL 7. Patients without heart failure
Exclusion criteria
Exclusion criteria: Patients who meet any exlusion criteria as bellow. 1. Patients who participate other clinical studies. 2. Patients who are pregnant. 3. Patients that the reseachers assess not suitable to join the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Part 1. To identify the protein profile adsorbed on PMMA membrane with proteimic analyisis. Part 2. To measure adsorption volume as well as reduction rate of beta2-microglobulin. | — |
Secondary
| Measure | Time frame |
|---|---|
| Part 1. N/A Part 2. To measure protein concentration adsorbed by PMMA membrane. Albumin, urea nitrogen, uric acid, creatinine, phosphate, beta2-microglobulin, alfa1-microglobulin, cystainC, leptin, myoglobin, prolactin, FLC kappa, FLC lamda, FGF-23, alfa1-glycoprotein, MMP-3, TNF-alfa, BTP, complement Factor D, HMGB-1, VEGF, YKL-40, visfatin, pentraxin-3, IL-6, IL-8, other molecules that are determined by proteomic analysis | — |
Contacts
Public ContactSuguru Yamamoto
Niigata University Medical and Dental Hospital
Outcome results
None listed